IκBα degradation is necessary for skeletal muscle atrophy associated with contractile claudication

Brian A. Hain, Stephen L. Dodd, and Andrew R. Judge

Departments of Applied Physiology and Kinesiology and Physical Therapy, University of Florida, Gainesville, Florida

Submitted 3 November 2010; accepted in final form 3 January 2011

EXERCISE CLAUDICATION IS A CONDITION ASSOCIATED WITH PERIPHERAL ARTERIAL DISEASE (PAD) THAT CONVEYS PAIN DURING WALKING DUE TO ISCHEMIA-INDUCED MUSCLE DAMAGE.

EXERCISE CLAUDICATION IS A CONDITION ASSOCIATED WITH PERIPHERAL ARTERIAL DISEASE (PAD) THAT CONVEYS PAIN DURING WALKING DUE TO ISCHEMIA-INDUCED MUSCLE DAMAGE.

EXERCISE CLAUDICATION IS A CONDITION ASSOCIATED WITH PERIPHERAL ARTERIAL DISEASE (PAD) THAT CONVEYS PAIN DURING WALKING DUE TO ISCHEMIA-INDUCED MUSCLE DAMAGE.

EXERCISE CLAUDICATION IS A CONDITION ASSOCIATED WITH PERIPHERAL ARTERIAL DISEASE (PAD) THAT CONVEYS PAIN DURING WALKING DUE TO ISCHEMIA-INDUCED MUSCLE DAMAGE.
Contractile claudication increases NF-κB transactivation and increases the expression of specific atrophy-related genes, and that repeated bouts of contractile claudication further increases these variables leading to skeletal muscle fiber atrophy.

MATERIALS AND METHODS

Animals

Male Sprague-Dawley rats (225 g) were purchased from Charles River Laboratories (Wilmington, MA, USA) and used for all subsequent experiments. All animal procedures were approved by the University of Florida Institutional Animal Care and Use Committee.

Expression and Reporter Plasmids

The enhanced green fluorescent protein (EGFP)-c1 plasmid was obtained from Clontech (Palo Alto, CA, USA) and the dominant-negative inhibitor of κB-EGFP [dominant-negative (d.n.) IkBα-EGFP, also referred to as IkBαΔN-EGFP] plasmid was created as previously described (26). The protein provided from this construct lacks amino acids 1–36 and, therefore, the serine 32 and serine 36 phosphorylation sites that are necessary for its subsequent degradation. The NF-κB-GL3 reporter plasmid contains a trimerized NF-κB site from the Igκ light-chain enhancer inserted into the IL-2 minimal promoter, driving expression of luciferase (gift from Dr. Steffan Ho). Plasmid DNA was prepared and isolated using an endotoxin-free maxi or mega prep kit (Qiagen, Valencia, CA).

Plasmid Injection

Plasmid injection and sequential transfection of skeletal muscle have been detailed previously (38, 49). Briefly, 10 μg of EGFP or d.n. IkBα-EGFP and 40 μg of the NF-κB reporter plasmid were injected into the soleus muscle in a total volume of 50 μl in 1 × PBS. Following injection, electric pulses were delivered using an electric pulse generator (Electro square porator ECM 830; BTX) by placing two paddle-like electrodes on each side of the muscle. Five pulses were delivered in 200-ms interpulse intervals, each with an effective intensity of 100 V/cm and 20-ms duration.

Contractile Claudication Model

The limbs of animals were assigned to a control (Con) group that underwent sham surgery, a ligated-only group that had the femoral artery ligated (Lig), a stimulated group that underwent in vivo electrical stimulation, to cause repeated muscle contractions and mimic exercise (Stim), and a ligated + stimulation group that had the femoral artery ligated followed, 2 days later, by in vivo electrical stimulation (Lig + Stim). We injected the soleus muscle of each of these groups with the EGFP expression plasmid 5 days prior to ligation or sham surgery. In an additional group of animals, the solei were injected with a d.n. IkBα-EGFP plasmid, and the limbs were assigned to a Lig + Stim group.

To perform the ligation surgery, animals were anesthetized with isoflurane (5% for induction, 1.5–2.5% for maintenance, delivered via O₂), placed in the prone position, and secured in a reproducible position with limited mobility of the lower leg except at the tibiotarsal joint. A stainless-steel stimulating electrode (cathode) was placed transcutaneously near the sciatic nerve midway between the posterior ischial spine and the greater femoral trochanter. Another electrode (anode) was inserted 3 mm subdermally in the midline of the lower back. Stimulations were administered at a frequency of 2 Hz at 100 V using a Grass 48 stimulator (Grass Technologies, West Warwick, RI).

In preliminary experiments stimulations were administered for one 30-min bout, and the soleus muscle was removed at various time points for measurement of NF-κB activity (0 min, 30 min, 60 min, 120 min, and 240 min poststimulation). In the subsequent “single bout of muscle contraction” experiments, stimulations were again administered for one 30-min bout, and the soleus muscle was removed 60 min poststimulation for measurement of NF-κB activity and 4 h following the bout for mRNA expression measurements. In the “repeated bouts of muscle contraction” experiments, stimulations were administered for 15 min, 4 times per day with 3 h between stimulation bouts, for 5 days. The soleus muscles were removed 60 min following the final bout for measurement of NF-κB activity and 4 h following the final bout for mRNA expression and muscle fiber cross-sectional area measurements.

The procedure of femoral artery ligation in the rat does not induce ischemia at rest due to the number of collateral and re-entrant vessels (48). However, during repeated muscle contractions, such as induced here via electrical stimulation, the increase in muscle blood flow is only 40% of the expected increase in control muscles (2). This is comparable to the increase in muscle blood flow in exercising PAD patients, which is ~50% of the increase in exercising control subjects (41). For these reasons, the model used here has previously been used by our group, and others, to mimic exercise claudication (17, 24, 25, 27). We have previously shown, using this model, that force production from the triceps surae muscle group decreases by ~10% in control limbs and ~50% in ligated limbs after 15 min of stimulation (24), and by ~15% and 70% in control and ligated limbs, respectively, after 30 mins of stimulation (24, 25, 27). The small decrease in control limbs demonstrates that the stimulation protocol is not intense.

Muscle Removal

Soleus muscles were removed under anesthesia (70 mg/kg pentobarbital sodium) and either processed immediately for RNA isolation—placed at a consistent length in OCT on a tongue depressor, which was immediately frozen in dry-ice-cooled isopentane and stored at −80°C for histochemical analysis—or frozen in liquid nitrogen and stored at −80°C for subsequent biochemical analyses.

NF-κB Reporter Activity

Following homogenization in a passive lysis buffer (Promega, Madison, WI) and centrifugation for 20 min at 5,000 g, 20 μl of the supernatant was added to 100 μl of luciferase reagent (Promega) for determination of total muscle luciferase activity, using an LMax II microplate luminometer (Molecular Devices, Sunnyvale, CA).

RNA Isolation, cDNA Synthesis, and RT-PCR

Total RNA was isolated from soleus muscles using the TRIzol-based method and cDNA synthesized using the RETROscript first-strand synthesis kit (Ambion, Austin, TX), as previously described (49). The concentration and quality of RNA were measured via the ratio of absorbance at 260 nm and 280 nm, and via agarose gel electrophoresis and staining to check for the integrity of 18 and 28S RNA. The 260/280 ratio in all samples, which ranged between 1.8 and 2.0. cDNA (5 μl), was then used as a template for real-time qPCR by using the following primer sets (Applied Biosystems, Carlsbad, CA): atrogin-1 (GenBank accession no. NM_133521), Muscle RING-finger...
protein-1 (MuRF1; GenBank accession no. NM_080903), neuronal precursor cell-expressed developmentally downregulated 4 (Nedd4; GenBank accession no. NM_012986.1), cathepsin L (GenBank accession no. NM_013156.1), and 18S (GenBank accession no. X03205.1). The sequences that Applied Biosystems use in designing these primers is proprietary and, therefore, not available to report. TaqMan probe-based chemistry (Applied Biosystems) was used to allow detection of PCR products on a 7300 ABI instrument, and quantitation of gene expression was performed using the relative standard curve method and normalized to 18S gene expression.

**Immunohistochemistry**

Cross sections (10 μm) were cut with a cryostat microtome (Microm International, Walldorf, Germany) from the midbelly of the soleus muscle and fixed in 4% paraformaldehyde. The muscle sections were incubated with wheat germ agglutinin Texas Red-X conjugate (Invitrogen, Carlsbad, CA) for visualization of muscle fibers under fluorescence microscopy, and images were captured with an Olympus IX50 camera. The muscle fiber area of ~250 fibers from each muscle was traced and measured using Image Pro Discovery software (Media Cybernetics, Bethesda, MD).

**Western blot analysis**

Protein concentrations of muscle homogenates were determined using a detergent-compatible assay (Bio-Rad, Hercules, CA, USA). Samples were diluted in loading buffer (Bio-Rad) containing 5% β-mercaptoethanol to achieve a protein concentration of 2 mg/ml and were heat denatured. Equal amounts of protein were loaded onto 4–15% linear gradient gels (Bio-Rad) and separated using SDS-PAGE. Proteins were transferred for 90 min at 100 V onto an Immobilon-FL polyvinylidene fluoride membrane (Millipore, Bedford, MA). The blots were blocked in PBS containing 5% milk and 0.05% Tween (blocking buffer) for 1 h at room temperature, and incubated overnight at 4°C with primary antibody diluted in blocking buffer. The following primary antibodies were used: anti-GFP (sc-8334; Santa Cruz Biotechnology, Santa Cruz, CA); anti-IκBα, 1:1,000 (sc-371; Santa Cruz Biotechnology); anti-MuRF1, 1:1,000 (sc-371; Santa Cruz Biotechnology); anti-MuRF1, 1:500 (MP3401; ECM Biosciences, Versailles, KY); anti-atrogin-1, 1:500 (AP2041; ECM Biosciences); anti-tubulin, 1:1,000 (T6074; Sigma-Aldrich, St. Louis, MO). Following a series of washes, the membranes were incubated with Alexa Fluor 680 or IRDye800 (LI-COR Biosciences, Lincoln, NE) fluorescent dye-conjugated secondary antibodies and visualized using the Odyssey infrared imaging system (LI-COR Biosciences, Lincoln, NE).

**Fig. 1.** NF-κB transcriptional activity following a single bout of contractile claudication. A: Preliminary data (bars represent means ± SE of 3 muscles per group) to determine the time course of NF-κB transactivation following a single bout of contractile claudication. B: NF-κB activity is significantly increased in the soleus muscle of Lig + Stim animals 1 h following the stimulation. Expression of the dominant-negative (d.n.) IκBα in Lig + Stim muscles abolished NF-κB activity. C: Endogenous IκBα protein expression and ectopically expressed d.n. IκBα protein expression, showing a 30% decrease in endogenous IκBα protein levels in the Lig + Stim group. Data for Lig + Stim (d.n. IκBα) are presented as a stacked bar to show endogenous IκBα and d.n. IκBα-EGFP expression. Bars for B and C represent means ± SE of six muscles per group. *P < 0.05 vs. all other groups.
Biosciences). Relative quantification of proteins was determined by measuring the fluorescence of each lane at the appropriate molecular weight.

Statistics

All data were analyzed using a one-way ANOVA for comparisons between each group, followed by Bonferroni corrections for multiple comparisons when appropriate (GraphPad Software, San Diego, CA). All data are expressed as means ± SE, and significance was established at the \( P < 0.05 \) level.

RESULTS

Single Bout of Muscle Contractions

**NF-κB activity.** Preliminary experiments were conducted to determine the optimal time point to measure NF-κB-dependent luciferase reporter activity following a 30-min single bout of contractile claudication (Fig. 1A). On the basis of these data, subsequent experiments on NF-κB-dependent reporter activity were conducted 1 h following the stimulation period. In these subsequent experiments, NF-κB activity was unchanged in muscles from the Lig only group, and muscles from the Stim only group compared with control, but increased >3-fold \( (P < 0.05) \) in muscles from the Lig + Stim group (Fig. 1B). Since IkBα is an endogenous inhibitory factor of NF-κB activity, we further sought to determine whether a decrease in IkBα expression is required for the Lig + Stim-induced NF-κB transactivation. To do this, we injected and electrotransferred a d.n. IkBα expression plasmid into the soleus muscle of a subset of rats prior to the Lig + Stim muscles expressing the d.n. IkBα. Furthermore, IkBα protein levels significantly decreased 30% in Lig + Stim muscles compared with all other groups \( (P < 0.05; \text{Fig. } 1\text{C}) \).

**mRNA expression of selected genes.** Quantitative RT-PCR was used to determine whether a single bout of contractile claudication increased the expression of specific genes known to be increased in multiple models of muscle atrophy, and to determine whether the d.n. IkBα affects the expression of these genes. We measured the mRNA expression of the E3 ubiquitin ligase genes, atrogin-1/MAFbx, MuRF1, Nedd4, and the lysosomal protease cathepsin L, 4 h following the stimulation bout. Atrogin-1 mRNA expression was unchanged across all groups (Fig. 2A). However, the mRNA expression of MuRF1, Nedd4, and cathepsin L was significantly increased in the Lig + Stim group 2.3-fold, 2-fold, and 1.9-fold, respectively, compared with control (Fig. 2, B–D). The increase in MuRF1 and cathepsin L in the Lig + Stim group was also significantly different to the Lig group and to the Stim group \( (P < 0.05) \). The increase in Nedd4 in the Lig + Stim group was significantly different to the Lig group \( (P < 0.05) \), but it did not reach significance compared with the Stim group \( (P = 0.09) \). Importantly, the increases in the mRNA expression of MuRF1, Nedd4, and cathepsin L in the Lig + Stim muscles were abolished in Lig + Stim muscles expressing the d.n. IkBα \( (P < 0.05) \). This suggests that MuRF1, Nedd4, and cathepsin L are NF-κB target genes (either direct or indirect).

Repeated Bouts of Muscle Contraction

**NF-κB activity.** Following repeated bouts of muscle contraction, NF-κB activity was unchanged in the Lig group compared with the control, but increased 6.5-fold in the Stim group and 18-fold in the Lig + Stim groups compared with control (Fig. 3A). However, this increase in NF-κB transcriptional activity in the Lig + Stim group was completely abolished in Lig + Stim muscles expressing the d.n. IkBα (Fig. 3A). These findings suggest, as with the single bout of muscle contraction, that IkBα degradation is necessary for NF-κB activation in this model of exercise claudication. Indeed, IkBα protein levels were decreased 67% in Lig + Stim muscles compared with controls (Fig. 3B).

**mRNA expression of selected genes.** Atrogin-1, MuRF1, Nedd4, and cathepsin L were significantly increased by 3.2-fold, 3.2-fold, 2.2-fold, and 3.2-fold, respectively, in the Lig + Stim muscles compared with controls (Fig. 3C–D). In contrast, IkBα protein levels were decreased 67% in Lig + Stim muscles compared with controls (Fig. 3B).
Muscle fiber atrophy. Since NF-κB is sufficient to cause skeletal muscle atrophy in vivo (7) and required for skeletal muscle atrophy associated with cancer cachexia (7) and disuse (7, 26, 55), we next sought to determine whether 1) repeated bouts of contractile claudication causes skeletal muscle atrophy, and 2) if so, whether NF-κB is required for this atrophy. Muscles in the Con, Lig, and Stim groups were injected with the EGFP-c1 plasmid, and the cross-sectional area of both green fluorescent fibers (i.e., those expressing EGFP) and black fibers (i.e., those fibers not transduced) was measured. Muscles in the Lig + Stim group were injected with the d.n. IκBa-EGFP plasmid and again the cross-sectional area of green fluorescent fibers (i.e., those expressing EGFP) and black fibers (i.e., those fibers not expressing the d.n. IκBa-EGFP) was measured. There were no differences between the mean cross-sectional area of transduced (green) or nontransduced (black) fibers in the Con, Lig, or Stim groups (Con black = 2,837 ± 176.2 μm²; Con green = 2,749 ± 90.67 μm²; Lig black = 2,872 ± 245.6 μm²; Lig green = 2,748 ± 152.3 μm²; Stim black = 2,755 ± 144.5 μm²; Stim green 2,834 ± 132.5 μm²). Five days of repeated bouts (15 min × 4 times/day) of contractile claudication (Lig + Stim group) decreased the mean fiber cross-sectional area by 35% in nontransduced fibers (i.e., black fibers, 1,834 ± 219.9 μm²). However, this decrease in muscle cross-sectional area was prevented in fibers from the Lig + Stim group expressing the d.n. IκBa-EGFP (2,942 ± 136.60 μm²). These findings clearly demonstrate that expression of EGFP alone has no effect on muscle fiber cross-sectional area, and suggest that NF-κB-IκBa signaling is required for the muscle atrophy associated with contractile claudication. No distinct evidence of muscle damage was observed in any group (Fig. 6, A–D).

**DISCUSSION**

Skeletal muscle mass and fiber cross-sectional area are significantly reduced in PAD patients compared with age-matched controls, which may be due to a variety of factors, including hypoxia, inactivity, hormonal imbalances, or alterations in the nutritional status of patients (10, 37, 45). In addition to these factors, there is evidence that plasma and muscle levels of cytokines and oxidants are chronically elevated in PAD patients, and further increased following exercise (6, 13, 18, 24, 28, 42, 50, 51, 53). Since both cytokines and oxidants can induce muscle protein loss through activation of various catabolic signaling pathways, these factors may also play a prominent role in the muscle atrophy associated with PAD. One such signaling pathway that is redox sensitive and potently activated by specific cytokines is the NF-κB signaling pathway (15, 33, 34), and NF-κB signaling is directly involved in the regulation of skeletal muscle mass (7, 21, 26, 55). However, to our knowledge, there are currently no data to suggest whether NF-κB activity is increased in the skeletal muscle of resting or exercising PAD patients. In the present study, we restricted blood supply to the hind limb of rodents and then superimposed repeated muscle contractions to mimic the condition of exercise in PAD patients, which we refer to here as contractile claudication. We show that NF-κB transcriptional activity is increased ~3-fold in the soleus muscle after a single bout of contractile claudication, and increased ~18-fold following repeated bouts of contractile claudication over 5 days. We further show, using in vivo gene transfer of a dominant-negative IκBa protein, that IκBa degradation and subsequent NF-κB activation are nec-
necessary for skeletal muscle atrophy associated with contractile claudication in our model.

NF-κB activity. The increase in NF-κB activity following contractile claudication was expected since acute and chronic exercise (19, 20, 22, 23), and ischemia-reperfusion (1, 35, 39, 44) all increase NF-κB activity in skeletal muscle, and exercise claudication is characterized by exercise-induced ischemia followed by recovery. However, our data not only demonstrate that contractile claudication significantly increases NF-κB transcriptional activity but that the magnitude of the increase in NF-κB-dependent reporter activity is greater with repeated bouts of contractile claudication over 5 days. Furthermore, overexpression of d.n. IκBα prevented the contractile claudication-induced increase in NF-κB activity, suggesting that IκBα degradation is necessary for contractile claudication-induced NF-κB activity. The lack of an increase in NF-κB activity following a single stimulation-only bout but an increase following repeated stimulation-only bouts is presumably a reflection of the mild stimulation protocol used that only generates sufficient stress to the muscle to activate NF-κB when applied repeatedly.

Atrophy-related genes. We also show in the current study that a single bout and repeated bouts of contractile claudication significantly increase the mRNA expression of specific genes that have been implicated in the regulation of muscle mass during various physiological conditions (26, 32, 52). However, the increased expression level of these atrophy genes is abolished in contractile claudicant muscles expressing the d.n. IκBα.

Fig. 4. mRNA levels of atrogin-1 (A), MuRF1 (B), Nedd4 (C), and cathepsin L (D) following repeated bouts of contractile claudication. Each gene is significantly increased in the Lig + Stim group, and this increase is abolished in Lig + Stim muscles expressing the d.n. IκBα. Bars represent means ± SE of six muscles per group. *P < 0.05 vs. all other groups.

Fig. 5. Representative Western blot with one sample from each group and bar graph of atrogin-1 (A) and MuRF1 (B) protein expression following repeated bouts of contractile claudication. Both atrogin-1 and MuRF1 protein levels are significantly increased in the Lig + Stim group, and this increase is abolished in Lig + Stim muscles expressing the d.n. IκBα. Bars represent means ± SE of six muscles per group. *P < 0.05 vs. all other groups.
IkBα. This confirms that, as previously shown (26), these genes are either direct or indirect NF-κB target genes. Atrogin-1, MuRF1, and Nedd4 are all E3 ubiquitin ligases that ubiquitinate specific protein substrates that are subsequently degraded by the lysosome or proteasome (8). Although the identification of targets of the various ubiquitin ligases in skeletal muscle is still in its infancy, some targets of atrogin-1, MuRF1, and Nedd4 have been identified.

Atrogin-1 and MuRF1 have received significant attention since the discovery that their independent absence in skeletal muscle significantly spares muscle mass during denervation (5). Atrogin-1 is now known to ubiquitinate and promote the degradation of eukaryotic initiation factor 3 subunit 5 (eIF3-f) (31) and suppresses MyoD transcriptional activity (30), both of which could lead to decreased muscle protein.

MuRF1 may play a significant role in promoting the degradation of myofibrillar proteins since myosin heavy chain (9), myosin-binding protein C (MyBP-C) (11), and myosin light chains 1 and 2 each undergo MuRF1-dependent degradation (11). Given that these myofibrillar proteins are involved in muscle contraction, their loss could affect muscle function. Therefore, the contractile claudication-induced increase in atrogin-1 and MuRF1 mRNA levels could be responsible, in part, for the decreased muscle fiber size discovered in the present study.

Nedd4 is associated with muscle atrophy, during which it ubiquitinates and down-regulates Notch1 (29). While the physi-
ological implications of Notch1 down-regulation in whole muscle during an atrophy condition are not clear, in adult skeletal muscle, Notch1 is required for satellite cell activation and proliferation and muscle regeneration (12). Given that the skeletal muscle of PAD patients are characterized by central-
ized nuclei (an indicator of muscle regeneration) (43), it is likely that regeneration is ongoing in the muscles of PAD patients and an increase in Nedd4, and subsequent decrease in Notch1, could negatively affect this. Cathepsin L is involved in the degradation of proteins in the lysosomes and is increased in multiple models of skeletal muscle atrophy, including disuse, cancer, sepsis, diabetes, and starvation (14, 26, 32, 46). However, the specific role of cathepsin L in the regulation of skeletal muscle mass is as yet unidentified.

The three-fold increase in NF-κB activity following a single bout of exercise claudication appears to be sufficient to increase MuRF1, Nedd4, and cathepsin L mRNA levels since the d.n. IkBα abolished NF-κB activity and the increased transcrip-
tion of these genes. However, the 6.5-fold increase in NF-κB activity following repeated stimulations only was not associated with the increased mRNA levels of these genes. This discrepancy could be due to the specific NF-κB Rel protein dimers and/or cofactors that MuRF1, Nedd4, and cathepsin L require for their transcription. Contractile claudication, but not contraction (stimulation) alone, may preferentially form dimers of Rel proteins and/or increase the presence or availability of cofactors that these genes require for their increased transcription.

Alternatively, differential epigenetic modification of histone proteins could explain the discrepancy. For example, acetylation of histones by acetyltransferase proteins promotes the unwinding of DNA and increased accessibility of gene promoters, whereas deacetylation of histones by deacetylases promotes the rewinding of DNA and gene silencing (47). If the cellular acetylation/deacetylation balance were tipped toward acetylation during contractile claudication, but toward deacety-
lation during contraction alone, this could promote chromatin relaxation at the MuRF1, Nedd4, and cathepsin L promoters only during contractile claudication. Under this scenario, des-
pite comparable increases in NF-κB reporter activity, in-
creased accessibility of these atrophy gene promoters to Rel proteins would only occur during contractile claudication. Clearly, this speculation warrants much further investigation.

Muscle fiber atrophy. The significant decrease in skeletal muscle fiber cross-sectional area found in the current study demonstrates that skeletal muscle fiber atrophy can occur following 5 days of repeated contractile claudication, as a model of exercise claudication. Therefore, although the presence of PAD and/or its associated comorbidities may contrib-
ute to the muscle atrophy in PAD patients, our findings, here, suggest that repeated bouts of exercise claudication may also be a major factor in the progression of muscle wasting in PAD patients. These data are in agreement with our previous find-
ings, using the same model, that showed contractile claudica-
tion increases markers of oxidative damage in skeletal muscle (24, 25, 27). Our results are also in conjunction with data from exercising PAD patients demonstrating that exercise increases plasma cytokine and oxidant levels (6, 13, 18, 28, 50, 51). On the basis of these findings, our results suggest that exercise claudication can have, at least short term, detrimental effects. Therefore, factors such as duration, frequency, and intensity of exercise should be considered when prescribing exercise to PAD patients to maximize the cardiovascular benefits of exercise, while minimizing the potentially detrimental systemic and muscular effects.

We also found that IkBα degradation and NF-κB activation are necessary for the muscle fiber atrophy associated with contractile claudication in our rodent model. Although we hypothesized that inhibition of NF-κB activity would attenuate muscle fiber atrophy because NF-κB is required for muscle fiber atrophy during muscle disuse (7, 21, 26, 55) and during cancer cachexia (7), the complete prevention of muscle fiber atrophy was unexpected. This suggests that either NF-κB is the sole activated signaling pathway leading to muscle fiber atrophy in our model or that inhibition of NF-κB activation subsequently represses the activation of an additional atrophy-
inducing signaling pathway.

In conclusion, contractile claudication, in a rodent model, significantly increases NF-κB transcriptional activity and the expression level of specific atrophy-related genes in skeletal muscle, and causes skeletal muscle fiber atrophy. Furthermore, gene transfer of d.n. IkBα abolished the increase in NF-κB activity, the increased transcription of atrophy genes and mus-
cle fiber atrophy associated with contractile claudication, dem-
onstrating that IkBα degradation is necessary for these pro-
cesses.

Perspectives and Significance

The findings of the current study, using a rodent model, suggest that repeated cycles of exercise claudication may play a role in the progression of muscle atrophy. This has poten-
tially important implications for PAD patients who undergo repeated cycles of physical activity-induced claudication each day, possibly for years. However, since exercise provides important overall cardiovascular benefits, it is important to better understand the influence of exercise on the skeletal muscle pathophysiology in PAD patients. Therefore, future work using both animal models and human tissue will further delineate the combined influence of exercise and blood flow restriction on skeletal muscle pathophysiology, so that novel and appropriate therapies may be developed.

ACKNOWLEDGMENTS

We thank Brittnay Gagnon and Jason Liounakos for technical assistance and Sarah Senf and Dr. Sarah Reed for editorial comments.

GRANTS

This work was supported by a James & Esther King Biomedical Research Program, Florida Department of Health Grant 08KN-07 (to A. R. Judge).

DISCLOSURES

No conflicts of interest, financial or otherwise, are declared by the authors.

REFERENCES

3. Anker SD, Chua TP, Ponikowski P, Harrington D, Swan JW, Kox WJ, Poole-Wilson PA, Coats AJ. Hormonal changes and catabolic/


